RCUS
HEALTHCAREArcus Biosciences Inc
$26.00-0.06 (-0.23%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving RCUS Today?
No stock-specific AI insight has been generated for RCUS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.91$28.72
$26.00
Fundamentals
Market Cap$3.3B
P/E Ratio—
EPS$-3.17
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding125.8M
RCUS News
20 articles- Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter ReportYahoo Finance·May 8, 2026
- Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead ShiftYahoo Finance·May 6, 2026
- Arcus Biosciences, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Arcus (RCUS) Q1 2026 Earnings Call TranscriptMotley Fool·May 5, 2026
- Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateYahoo Finance·May 5, 2026
- Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive OfficerYahoo Finance·May 5, 2026
- Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?Yahoo Finance·May 4, 2026
- Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·Apr 29, 2026
- Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·Apr 28, 2026
- Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option ShiftYahoo Finance·Apr 25, 2026
- Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILDYahoo Finance·Apr 24, 2026
- Arcus Biosciences Announces New Employment Inducement GrantsYahoo Finance·Apr 24, 2026
- Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?Yahoo Finance·Apr 22, 2026
- Merck adds to pharma’s AI push; Roche details MS drug resultsBiopharmadive·Apr 22, 2026
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline UpdatesYahoo Finance·Apr 21, 2026
- 5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up247 Wall St·Apr 1, 2026
- Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center StageYahoo Finance·Mar 2, 2026
- Arcus Biosciences Q4 Earnings Call HighlightsMarketbeat·Feb 28, 2026
- RCKT's Q4 Loss Narrower Than Estimated, Pipeline in FocusYahoo Finance·Feb 27, 2026
All 20 articles loaded
Price Data
Open$25.02
Previous Close$26.06
Day High$26.28
Day Low$24.20
52 Week High$28.72
52 Week Low$7.91
52-Week Range
$7.91$28.72
$26.00
Fundamentals
Market Cap$3.3B
P/E Ratio—
EPS$-3.17
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding125.8M
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—